The goal of this CIRM New Cell Line award is to derive new pluripotent stem cell lines from human embryos for research, and also to develop the conditions for deriving embryonic stem cell lines by current good manufacturing practice. In this reporting period we are documenting the derivation of twenty one new embryonic stem cell lines. Nineteen lines have been Karyotyped, and twelve out of nineteen are diagnosed as euploid with a karyotype of either 46, XX or 46, XY. Three of the karyotypically normal cell lines (UCLA-1, UCLA-2 and UCLA-3), have been registered in the NIH stem cell registry as well as registered at CIRM. One of the aneuploid cell lines represents a new disease model for Trisomy 21.